Table 2:
Overall outcome and efficacy of avacopan treated patients with hypoxic pulmonary haemorrhage in ANCA-associated vasculitis.
| Patient | ICU Y/N, duration | Mechanical ventilation (invasive/non-invasive), duration | Oxygen requirement, duration, flow (max) | Haemoglobulin, lowest level (g/L) | Total duration of 1st hospitalization, re-hospitalization | Lung symptoms resolutiona, duration | Total follow-up (months) | Survival | Last FU: eGFR (mL/min/1.73 m2), ACR (mg/mmol) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Y, 6 days | Non-invasive mechanical ventilation (6 days) | • 10 days• 15 L/min | 79 | • 16 days• N | Resolved, 13 days | 9 | Y | • 30• 54 |
| 2 | Y, 60 days | Invasive mechanical ventilation (43 days), ECMO (60 days) | • 70 days• Mechanical ventilation | 82 | • 85 days• N | Resolved, 70 days | 13 | Y | • 140• 0.2 |
| 3 | Y, 7 days | Invasive mechanical ventilation (4 days) | • 16 days• Mechanical ventilation | 62 | • 21 days• N | Resolved, 16 days | 6 | Y | • 5 (HD)• 98 |
| 4 | N | N | • 16 days • 4 L/min | 87 | • 17 days• N | Resolved16 days | 2 | Y | • 24• 45 |
| 5 | N | N | • 5 days• 3 L/min | 76 | • 9 days• N | Resolved, 7 days | 6 | Y | • 82• neg |
| 6 | Y, 11 days | Invasive mechanical ventilation (7 days) | • 11 days• Mechanical ventilation | 53 | • 85 days• N | Resolved, 32 days | 3 | Y | • 10 (HD)• N/A |
| 7 | N | N | • 2 days• 15 L/min | 74 | • 78 days• N | Resolved, 90 days | 10 | Y | • 107Without kidneyinvolvement |
| 8 | N | N | • 9 days• 15 L/min | 92 | • 10 days• N | Resolved, 9 days | 5 | Y | • 53• PCR = 20 |
a
Off oxygen treatment, without haemoptysis and stable haemoglobulin.
Y, yes; N, no; max, maximum; N/A, not available; ACR, albumin–creatinine ratio (mg/mmol); neg, negative; PCR, protein–creatinine ratio (mg/mmol); FU, follow-up, HD, haemodialysis.